Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Godfrey

Showing results (291-300 of 321) with videos related to

Pageof 33
Sort By:
Frontiers in Immunology|August 15, 2022
Fc engineered ACE2-Fc is a potent multifunctional agent targeting SARS-CoV2Bruce D Wines, Liriye Kurtovic, Halina M Trist, et al.
Iscience|October 10, 2022
Biparatopic nanobodies targeting the receptor binding domain efficiently neutralize SARS-CoV-2Phillip Pymm, Samuel J Redmond, Olan Dolezal, et al.
The Journal of Experimental Medicine|May 31, 2019
TCF-1 limits the formation of Tc17 cells via repression of the MAF-RORγt axisLisa A Mielke, Yang Liao, Ella Bridie Clemens, et al.
Nature Communications|August 24, 2018
MAIT cells protect against pulmonary Legionella longbeachae infectionHuimeng Wang, Criselle D'Souza, Xin Yi Lim, et al.
Clinical & Translational Immunology|February 28, 2018
Rapid loss of group 1 innate lymphoid cells during blood stage <i>Plasmodium</i> infectionSusanna S Ng, Fernando Souza-Fonseca-Guimaraes, Fabian de Labastida Rivera, et al.
Organic & Biomolecular Chemistry|January 19, 2019
Enhancing T cell responses and tumour immunity by vaccination with peptides conjugated to a weak NKT cell agonistBenjamin J Compton, Kathryn J Farrand, Ching-Wen Tang, et al.
Frontiers in Immunology|January 27, 2023
Corrigendum: Fc engineered ACE2-Fc is a potent multifunctional agent targeting SARS-CoV2Bruce D Wines, Liriye Kurtovic, Halina M Trist, et al.
Science (New York, N.Y.)|January 11, 2020
Butyrophilin 2A1 is essential for phosphoantigen reactivity by γδ T cellsMarc Rigau, Simone Ostrouska, Thomas S Fulford, et al.
NPJ Vaccines|January 17, 2026
Preclinical development of a cross-protective β-SARS-CoV-2 virus-like particle vaccine adjuvanted with MF59Linda Earnest, Daniel Fernandez Ruiz, Melissa A Edeling, et al.
Molecular Therapy. Methods & Clinical Development|December 17, 2024
mRNA vaccines encoding membrane-anchored RBDs of SARS-CoV-2 mutants induce strong humoral responses and can overcome immune imprintingHareth A Al-Wassiti, Stewart A Fabb, Samantha L Grimley, et al.
Pageof 33

Showing results (291-300 of 321) with videos related to

Sort By:
Pageof 33
Frontiers in Immunology|August 15, 2022
Fc engineered ACE2-Fc is a potent multifunctional agent targeting SARS-CoV2Bruce D Wines, Liriye Kurtovic, Halina M Trist, et al.
Iscience|October 10, 2022
Biparatopic nanobodies targeting the receptor binding domain efficiently neutralize SARS-CoV-2Phillip Pymm, Samuel J Redmond, Olan Dolezal, et al.
The Journal of Experimental Medicine|May 31, 2019
TCF-1 limits the formation of Tc17 cells via repression of the MAF-RORγt axisLisa A Mielke, Yang Liao, Ella Bridie Clemens, et al.
Nature Communications|August 24, 2018
MAIT cells protect against pulmonary Legionella longbeachae infectionHuimeng Wang, Criselle D'Souza, Xin Yi Lim, et al.
Clinical & Translational Immunology|February 28, 2018
Rapid loss of group 1 innate lymphoid cells during blood stage <i>Plasmodium</i> infectionSusanna S Ng, Fernando Souza-Fonseca-Guimaraes, Fabian de Labastida Rivera, et al.
Organic & Biomolecular Chemistry|January 19, 2019
Enhancing T cell responses and tumour immunity by vaccination with peptides conjugated to a weak NKT cell agonistBenjamin J Compton, Kathryn J Farrand, Ching-Wen Tang, et al.
Frontiers in Immunology|January 27, 2023
Corrigendum: Fc engineered ACE2-Fc is a potent multifunctional agent targeting SARS-CoV2Bruce D Wines, Liriye Kurtovic, Halina M Trist, et al.
Science (New York, N.Y.)|January 11, 2020
Butyrophilin 2A1 is essential for phosphoantigen reactivity by γδ T cellsMarc Rigau, Simone Ostrouska, Thomas S Fulford, et al.
NPJ Vaccines|January 17, 2026
Preclinical development of a cross-protective β-SARS-CoV-2 virus-like particle vaccine adjuvanted with MF59Linda Earnest, Daniel Fernandez Ruiz, Melissa A Edeling, et al.
Molecular Therapy. Methods & Clinical Development|December 17, 2024
mRNA vaccines encoding membrane-anchored RBDs of SARS-CoV-2 mutants induce strong humoral responses and can overcome immune imprintingHareth A Al-Wassiti, Stewart A Fabb, Samantha L Grimley, et al.
Pageof 33